NRCME Diabetes Mellitus Standards 5

Question 1

A commercial driver with diabetes is found to have microalbuminuria. This is most relevant to the examiner because it indicates:

Accepted Answer

Early diabetic kidney disease and elevated cardiovascular risk

Answer

Microalbuminuria signals early nephropathy and is a marker of systemic vascular disease that elevates overall cardiovascular risk.

Question 2

When a driver with diabetes reports using a continuous glucose monitor (CGM), the examiner should understand that:

Accepted Answer

CGM is a monitoring tool and does not change FMCSA qualification requirements

Answer

CGM is a useful monitoring device but does not alter the legal qualification framework; drivers must still meet all FMCSA standards.

Question 3

A driver with diabetes reports blurred vision that resolves after glucose correction. This symptom is medically significant because it suggests:

Accepted Answer

Episodic hypoglycemia or hyperglycemia causing transient visual changes that impair driving

Answer

Transient vision changes tied to glucose fluctuation indicate glycemic instability that can impair driving safely.

Question 4

What is the primary reason FMCSA originally prohibited insulin-treated drivers from interstate commerce?

Accepted Answer

Risk of hypoglycemia causing sudden incapacitation while driving

Answer

The original prohibition was based on the risk that hypoglycemia could cause sudden loss of cognitive function or consciousness at the wheel.

Question 5

A driver with Type 2 diabetes switches from metformin to a GLP-1 receptor agonist. From an FMCSA standpoint, the primary consideration is:

Accepted Answer

GLP-1 agents have low hypoglycemia risk and generally do not change certification status

Answer

GLP-1 receptor agonists have a very low hypoglycemia risk when used without insulin, so they typically do not trigger additional FMCSA restrictions.

NRCME - National Registry of Certified Medical Examiners Practice Test